Homechevron_rightNewschevron_rightMedia Releasechevron_rightHatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

12 December 2013

Posted in — Media Release

Share

Learn More

Posted in — Media Release

Share

chevron_leftPreviosly

Australia’s Hatchtech ‘itching’ to partner at J.P. Morgan

27 January 2014

Nextchevron_right

Looking for investment? Here's what you need to include in your pitch deck

06 December 2013

View All

Subscribe to our Newsletter for the latest updates from 1V.

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

Australia’s Hatchtech ‘itching’ to partner at J.P. Morgan

Looking for investment? Here's what you need to include in your pitch deck

You may also like

Clinical Genomics Strenghtens it’s Leadership Team with Multiple Key Appointments

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S.

charmhealth names Gary Lakin as new CEO

OneVentures reaches first close of Australia’s first venture credit fund

Pearson acquires interactive learning technology from Smart Sparrow

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.